---
title: "U.S. stock night market opening fluctuations: Humana rose 12.78% in night trading; 9F fell 11.47% in night trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281808164.md"
description: "Humana night trading rose 12.78%; 9F night trading fell 11.47%; Organogenesis night trading rose 21.88%; LiXiang Education night trading rose 16.75%; iRobot night trading rose 8.05%"
datetime: "2026-04-07T00:06:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281808164.md)
  - [en](https://longbridge.com/en/news/281808164.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281808164.md)
---

# U.S. stock night market opening fluctuations: Humana rose 12.78% in night trading; 9F fell 11.47% in night trading

**U.S. Stock Night Market Opening Movements**

Humana rose 12.78% in the night market. Based on recent key news:

1.  On April 6, the U.S. government announced that the payment rates for the federal Medicare Advantage program will increase by 2.48% in 2027, significantly higher than the proposed 0.09% in January. This news boosted the stock prices of insurance companies, including Humana, which saw its stock rise about 12% in after-hours trading. Source: CNBC
    
2.  On April 6, Dr. Mohammed Oz, head of CMS, stated that the new payment standards will maintain the affordability of insurance coverage and ensure that patients receive tangible value from their insurance plans. This policy adjustment is favorable for companies like Humana, driving their stock prices up. Source: CNBC
    
3.  On April 6, Humana released its 2025 impact report, highlighting progress in achieving simpler and more affordable healthcare. This positive company news also supported the stock price. Source: Business Wire The increase in Medicare payments is beneficial for insurance companies.
    

9F fell 11.47% in the night market, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

**Top Gainers in the U.S. Stock Night Market**

Organogenesis rose 21.88% in the night market. Based on recent key news:

1.  On April 6, Organogenesis announced that its PuraPly®AM achieved its primary endpoint in a randomized controlled trial, showing significant effects in treating non-healing diabetic foot ulcers. This result enhances the clinical evidence for PuraPly, supporting its inclusion in future insurance policies and driving the stock price up.
    
2.  On April 6, Organogenesis successfully completed a meeting with the FDA and plans to submit a Biologics License Application (BLA) for ReNu® for knee osteoarthritis pain. This progress paves the way for the commercialization of ReNu, boosting market confidence.
    
3.  On April 6, Organogenesis announced that it will release its Q1 2026 financial report on May 7, and investors have shown strong interest in the upcoming financial data, further driving the stock price up. The biotechnology sector has been active recently, with a noticeable inflow of funds.
    

Li Xiang Education rose 16.75% in the night market, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

iRobot rose 8.05% in the night market, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation

### Related Stocks

- [HUM.US](https://longbridge.com/en/quote/HUM.US.md)
- [JFU.US](https://longbridge.com/en/quote/JFU.US.md)

## Related News & Research

- [Humana, CenterWell and USAA Unite with VFW for National Day of Service Supporting Veterans Experiencing Homelessness | HUM Stock News](https://longbridge.com/en/news/286416098.md)
- [Humana Stock Outlook: Is Wall Street Bullish or Bearish?](https://longbridge.com/en/news/286555080.md)
- [Retirees: Buy this ETF for long-term stability and high dividends](https://longbridge.com/en/news/286943591.md)
- [Where Nike’s marketing comeback is stumbling — and where it can still win](https://longbridge.com/en/news/286939325.md)
- [Goldman's Pasquariello Sees "Cause For Some Momentum Sobriety"](https://longbridge.com/en/news/286791105.md)